TITLE

Sensitivity to a Neurosteroid Is Increased during Addition of Progestagen to Postmenopausal Hormone Replacement Therapy

AUTHOR(S)
Wihlbäck, Anna-Carin; Sundström-Poromaa, Inger; Nyberg, Sigrid; Bäckström, Torbjörn
PUB. DATE
June 2001
SOURCE
Neuroendocrinology;2001, Vol. 73 Issue 6, p397
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The aim of this study was to compare the pharmacodynamic response to a neuroactive steroid, pregnanolone, before and during different hormonal settings of postmenopausal hormone replacement therapy (HRT). Twenty-seven postmenopausal women with climacteric symptoms were administered HRT in a randomized, double-blinded, placebo-controlled crossover study. The women received 2 mg estradiol (E[sub 2] ) continuously during four 28-day cycles and 10 mg medroxyprogesterone acetate (MPA), 1 mg norethisterone acetate (NETA) or placebo sequentially for the last 14 days in each cycle. The pharmacodynamic response to pregnanolone was assessed before treatment and during the last week of each treatment, by comparing the effects of intravenous pregnanolone (3α-hydroxy-5β-pregnan-20-one) on saccadic eye velocity (SEV), saccade deceleration, saccade latency and self-rated sedation. Throughout the study daily symptom rating scales were kept. During the progesta gen phase of the treatment cycles, negative mood symptoms and physical symptoms were increased, whereas positive mood symptoms were decreased. Compared to pretretreatment conditions, E[sub 2] alone did not change the responsiveness to pregnanolone. During progestagen addition to E[sub 2] , the responsiveness to pregnanolone was increased. The sedation response increased compared to pretreatment conditions during both E[sub 2] + MPA and E[sub 2] + NETA treatment. Compared to E[sub 2] treatment alone, addition of MPA increased the postpregnanolone effect on saccade deceleration, whereas the SEV response to pregnanolone was increased during E[sub 2] + NETA treatment. It is concluded that pregnanolone sensitivity increases together with deterioration in mood symptoms during addition of progestagen to HRT.Copyright © 2001 S. Karger AG, Basel
ACCESSION #
11374044

 

Related Articles

  • 2008 - Risk for cancer was still increased over 2 years after stopping hormone therapy. Cheung, Angela M. // ACP Journal Club;8/19/2008, Vol. 149 Issue 2, p9 

    The article focuses on a study regarding the health risks associated in postmenopausal women after stopping hormone therapy (HT) and presents the author's views on it. It describes the procedure of the study, which revealed that the risk of cancer increased in postmenopausal women, over 2 years...

  • Hormone therapy: Benefits of a combined regimen.  // American Family Physician;2/15/1996, Vol. 53 Issue 3, p962 

    Presents the study `Combined Continuous Hormone Replacement Therapy: A Critical Review,' by L. Udoff, et al., published in the 1995 issue of `Obstetrics and Gynecology.' Result of the clinical trial on the effectiveness of combined estrogen and progestin therapy; Complications prevented by...

  • Brain Regions Activated during an Auditory Discrimination Task in Insomniac Postmenopausal Patients before and after Hormone Replacement Therapy: Low-Resolution Brain Electromagnetic Tomography Applied to Event-Related Potentials. Saletu, Bernd; Saletu-Zyhlarz, Gerda; Gruber, Doris; Metka, Markus; Huber, Johannes; Pascual-Marquic, Roberto D.; Anderer, Peter // Neuropsychobiology;2004, Vol. 49 Issue 3, p134 

    Electrical sources of auditory event-related potentials (ERPs) determined by means of low-resolution brain electromagnetic tomography (LORETA) in 48 unmedicated insomniac postmenopausal patients aged between 46 and 67 years were compared with those obtained in 48 age-matched normal female...

  • Estrogen overload. Torkos, Sherry // Alive: Canada's Natural Health & Wellness Magazine;Jul2008, Issue 309, p58 

    The article examines serious effects of estrogen overload in the health of women. A Women's Health Initiative (WHI) Memory Study has found that estrogen plus progestin doubles the risk for developing dementia among postmenopausal women who are 65 years and older. The use of replacement therapy...

  • A Syndrome of Psychosis following Discontinuation of an Estrogen-Progestogen Contraceptive and Improvement following Replacement: A Case Report. Huber; Nickel; Tröger; Schneider; Husstedt; Emrich // Neuropsychobiology;1999, Vol. 40 Issue 2, p75 

    Mild forms of psychosis associated with low estrogen levels during the perimenopause are relatively frequent. There is scarce data on severe forms of psychosis in these conditions. We report the case of a 51-year-old woman with no previous psychiatric history who amputated her hand in a...

  • Progesterone.  // AHFS Consumer Medication Information;Jun2020, p1 

    Progesterone is used as a part of hormone replacement therapy in women who have passed menopause (the change of life) and have not had a hysterectomy (surgery to remove the uterus). Hormone replacement therapy usually includes estrogen, which is used to treat symptoms of menopause and reduce the...

  • Effects of Hormonally Active Agents on Steroid Hormone Receptor Expression and Cell Proliferation in the Myometrium of Ovariectomized Macaques. HILL, GEORGETTE D.; MOORE, ALICIA B.; KISSLING, GRACE E.; FLAGLER, NORRIS D.; NEY, ELIZABETH; CLINE, J. MARK; DIXON, DARLENE // Toxicologic Pathology;Apr2011, Vol. 39 Issue 3, p508 

    Hormone replacement therapy and selective estrogen receptor modulators have been controversial treatment options for postmenopausal women because of their potential health benefits and/or risks. In this study, we determine the effects of the hormonally active compounds, conjugated equine...

  • Researchers explore DHEA for postmenopausal health. Pirisi, Angela // Life Extension;Feb2002, Vol. 8 Issue 2, p22 

    Investigates the importance of dehydroepiandrosterone (DHEA) on postmenopausal health. Reduction in depression and anxiety symptoms; Role of DHEA in regulating several endocrine functions; Effect of strogenic activity on hormone secretion.

  • Metabolic effects of hormone replacement regimens.  // American Family Physician;7/1/1996, Vol. 54 Issue 1, p302 

    Reports on a study conducted by the British Medical Research Council published in the 1996 issue of the `British Medical Journal' periodical concerning the metabolic effects of hormone replacement regimens for postmenopausal women. Comparison of the acceptability, side effects and metabolic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics